verdiperstat

News

Four more drugs in keenly watched ALS trial miss the mark

ALS candidates from Biohaven, Prilenia, Clene, and UCB were unable to slow disease progression in the study, but two showed signs of efficacy.

News

Bad news for Biohaven as verdiperstat flunks first phase 3 t...

Biohaven's key pipeline drug verdiperstat has failed to have any therapeutic effect in patients with the rare neurological disorder multiple system atrophy (MSA) – its lead indication – but

News

Lundbeck preps for key bexicaserin data around year-end

Lundbeck has completed patient randomisation in a pivotal trial of epilepsy candidate bexicaserin, one of its major growth hopes.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks